Study drug before and after lung surgery for stage II–III cancer
Part of Cancer, Lungs & breathing clinical trials.
This Phase II trial tests whether a penpulimab-based combination treatment, given before and after surgery, can improve outcomes for people with operable, locally advanced non-small cell lung cancer. It mainly aims to treat the cancer earlier (before surgery) and help prevent it from coming back (after surgery).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that can be removed by surgery (stage IIB to IIIB, including N2 lymph nodes), confirmed by tissue testing
- Your tumor does NOT have EGFR, ALK, or ROS1 gene fusion mutations in the original tumor or lymph node spread
- Your recent health is good (ECOG 0–1) and you can safely undergo lung surgery, with at least 12 weeks expected survival
- You have not had any prior cancer treatments for this lung cancer, including surgery, chemotherapy, radiation, or other anti-cancer medicines
- You cannot have certain lung cancer types (like large cell or mixed cell) or a history of lung inflammation from prior treatments
- You must be able to take oral study medicine and avoid pregnancy; no serious recent blood-vessel clotting events or recent strokes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of drugs (including pembrolizumab) as a treatment before surgery for people with a certain type of lung cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial studies whether giving a PD-1 antibody together with standard chemotherapy before surgery can improve outcomes for people with stage IIIB–IIIC non-small cell lung cancer. It aims to shrink or control the cancer and make treatment before surgery more effective.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
Hear when a new Resectable Locally Advanced Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.